The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 50 results
December 2024
-
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™
Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancerMontreal, Quebec, December 13, 2024 –… -
Media Release
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity
The Novartis Health Equity Initiative was launched earlier this year as a call for ideas to help tackle persistent health disparities and promote equal access to healthcare in CanadaSubmissions were…
August 2024
-
Story Global Impact
Enabling early detection of psoriatic arthritis
-
Story Global Impact
Biomarker research to help modernize care in multiple sclerosis
-
Story Global Impact
My Krew
-
Media Release
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy
Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers Montreal, August 20, 2024 —…
May 2024
-
Media Release
NOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIP
Psoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the… -
Media Release
Health Canada approves Cosentyx®, a biologic therapy, for the treatment of adults with moderate to severe Hidradenitis Suppurativa (HS)
Approval is based on the two largest Phase III trials conducted in HS – SUNSHINE and SUNRISE – demonstrating the safety and efficacy of Cosentyx® in HS1HS is a chronic, immunological, inflammatory…